Pomalidomide — Drug Intelligence | 42 EU Trials

Filter these 42 trials by condition, phase, country and more.

Open in Search →

42 Registered trials

9 Recruiting

27 Completed trials

23 Sponsors

23 Countries

Phase III

Phase II

Phase I/II

Phase III: 24 Phase II: 10 Phase I/II: 7 Phase I (FiH): 1

Oversight events:

2 urgent safety measures 2 unexpected events 2 corrective measures across 4 trials

View oversight register →

Indications tested

Plasma cell myeloma 4 Acute myeloid leukaemia 1 Non-Hodgkin's lymphoma 1 Myelodysplastic syndrome 1 Plasma cell myeloma refractory 1 Amyloidosis 1 Plasma cell myeloma recurrent 1

Sponsors using this IMP

Janssen - Cilag International 6 Celgene Corp. 4 Glaxosmithkline Research & Development Limited 4 AbbVie Deutschland GmbH & Co. KG 3 Sanofi-Aventis Recherche & Developpement 3 Hellenic Society Of Hematology 2 Pfizer Inc. 2 Regeneron Pharmaceuticals Inc. 2 Region Midtjylland 2 AstraZeneca AB 1 BeOne Medicines AG 1 Cellcentric Limited 1

All trials

42 total

Daratumumab in Combination with Carfilzomib, Pomalidomide and Dexamethasone in patients with myeloma induced acute renal failure Pending

2024-514702-31-00 Phase II 1 country Medizinische Universitaet Innsbruck
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy with Standard-of-Care Combination Regimens … Pending

2024-519504-27-00 Phase III 10 countries Regeneron Pharmaceuticals Inc.
A Phase II, Open-label, Multicenter Study Testing Teclistamab in Combination with Pomalidomide Administered in Alternative Fashion in Partic… Pending

2025-522114-23-00 Phase II 4 countries Odense University Hospital
A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma. Pending

2025-523285-25-00 Phase III 6 countries AstraZeneca AB
Cevostamab in Combination with Pomalidomide and Dexamethasone Versus Standard of Care in Patients with Previously Treated Multiple Myeloma Pending

2025-524028-23-00 Phase III 2 countries F. Hoffmann-La Roche AG
A study investigating the safety and efficacy of academically-produced CAR T cells compared with standard treatment for patients with multip… Pending

2025-524876-43-00 Phase III 1 country Universitair Medisch Centrum Groningen
A study to evaluate the efficacy and safety of belantamab mafodotin in combination with standard of care in participants aged 18 years and o… Recruiting

2025-523117-28-00 Phase II 5 countries Glaxosmithkline Research & Development Limited
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax (ABBV-453) Alone or in Combination With Subcutaneous and… Recruiting

2024-517140-65-00 Phase I/II 7 countries AbbVie Deutschland GmbH & Co. KG
Pomalidomide in people with chronic hepatitis B virus (HBV) infection: Safety and immune-enhancing effects (The PIPPI Study) Recruiting

2025-521030-29-00 Phase I/II 1 country Region Midtjylland
A first time in man study to look at the safety of the experimental drug CCS1477 and what effects it has on cancers that affect the blood, b… Recruiting

2024-519498-20-00 Phase I/II 1 country Cellcentric Limited
A Phase 3 Study of a GPRC5D-directed CAR T Cell Therapy in Participants with Relapsed or Refractory Multiple Myeloma and Exposed to Lenalido… Recruiting

2024-515279-37-00 Phase III 17 countries Celgene Corp.
Pomalidomide as an immune-enhancing agent for the control of HIV (PEACH) Recruiting

2024-512797-10-00 Phase I/II 2 countries Region Midtjylland
A Phase 1b/2 Study of BGB-11417 as Monotherapy and in Various Combinations with Dexamethasone plus Carfilzomib, Dexamethasone plus Daratumum… Recruiting

2023-507751-30-00 Phase I/II 5 countries BeOne Medicines AG
C1071032 - MAGNETISMM-32 A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMAL… Recruiting

2023-507871-23-00 Phase III 16 countries Pfizer Inc.
Isatuximab in combination with novel agents in RRMM – Master protocol and control arm Recruiting

2024-514988-25-00 Phase I/II 6 countries Sanofi-Aventis Recherche & Developpement
Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma Ended

2024-511188-26-00 Phase III 9 countries Kite Pharma Inc.
A Phase 3 study of Etentamig vs Standard Available Therapies in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) (3L+ RRMM Monot… Ended

2023-506668-15-00 Phase III 13 countries AbbVie Deutschland GmbH & Co. KG
A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-… Ended

2022-502446-27-00 Phase III 13 countries Janssen - Cilag International
A Study to Learn How Linvoseltamab (REGN5458) Will Work Compared to the Elotuzumab, Pomalidimide and Dexamethasone (EPd) Combination, in Par… Ended

2022-501396-62-00 Phase III 7 countries Regeneron Pharmaceuticals Inc.
International treatment-extension study in adult participants with multiple myeloma and who have derived clinical benefit from isatuximab Ended

2023-507180-19-00 Phase II 7 countries Sanofi-Aventis Recherche & Developpement
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethas… Ended

2023-503444-13-00 Phase III 13 countries Janssen - Cilag International
A Clinical Study to evaluate the long-term safety of Daratumumab in combination with standard bone marrow cancer treatment regiments Ended

2022-500138-27-01 Phase III 9 countries Janssen - Cilag International
A PHASE 1/2, DOSE AND SCHEDULE EVALUATION STUDY TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN ADMINISTERED IN COMB… Ended

2024-516147-32-00 Phase I/II 1 country Hellenic Society Of Hematology
SC versus IV isatuximab in combination with pomalidomide and dexamethasone in RRMM Ended

2023-508869-32-00 Phase III 10 countries Sanofi-Aventis Recherche & Developpement

Showing 1–24 of 42 trials

← All drugs A–Z